JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?
نویسندگان
چکیده
منابع مشابه
jak2-v617f mutation and philadelphia positive chronic myeloid leukemia
jak2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. a single acquired point mutation – v617f – in jak2 occurs in the great majority of patients with polycythemia vera (pv) and approximately half of the patients with idiopathic myelofibrosis (imf) or essential thrombocythemia (et). in contrast, the jak2-v617f mutation is...
متن کاملTerminal deoxynucleotidyl transferase activity in non-hematologic and hematologic neoplasms.
The presence of terminal deoxynucleotidyl transferase (TdT) has been determined in neoplastic cells from 50 patients with non-hematologic tumors as well as neoplastic cells from 85 patients with hematologic malignancies. The results indicate that TdT is not present in cells from non-hematologic tumors, Hodgkin's lymphoma, B cell lymphoproliferative disorders, peripheral T cell neoplasms, reacti...
متن کاملHydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.
A recent publication by Antonioli et al. shows that the continuous use of hydroxyurea (HU) does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera (PV) or essential thrombocythemia (ET). Our results confirm and extend these data. To assess the effects of a cytoreductive treatment on the JAK2-V617F allelic ratio, a single center retrospective study in myeloprolife...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomarker Research
سال: 2016
ISSN: 2050-7771
DOI: 10.1186/s40364-016-0073-4